Vasopresin and human hypertension.
1. Two clinical studies are reported which investigate: (1) the regulation of vasopressin release in moderate hypertensive subjects not under treatment compared to normotensives and, (2) the effects of antihypertensive treatment on vasopressin and on its osmoregulation in moderate hypertensives. 2. In the first study two stimuli facilitating vasopressin release (active upright position and hypertonic saline infusion) and a stimulus inhibiting vasopressin release (hypotonic saline infusion) have been applied to 13 moderate essential hypertensives and 8 control normotensives. In the second study, limited to hypertensives, the effects on plasma vasopressin and other plasma and urine variables, of either acute (by clonidine, n = 6 or by sodium nitroprusside, n = 6) or chronic (antihypertensive treatment for 1 month, n = 8) blood pressure lowering, before and after the i.v. administration of a hypertonic NaCl solution, were investigated. 3. Baseline plasma vasopressin was not different in hypertensive and in normotensive subjects. Upright posture and hypertonic challenge augmented, while hypotonic saline reduced plasma vasopressin levels with no difference between the two groups. Acute, but not chronic, lowering of blood pressure increased plasma vasopressin from 1.6 +/- 0.63 to 3.4 +/- 0.7 pg/mL (p < 0.05); administration of hypertonic saline further increased vasopressin to 10.8 +/- 2.22 (p < 0.01) in the acute and to 6.0 +/- 1.03 pg/mL (p < 0.01) in the chronic study. 4. No significant alterations of the regulation of vasopressin have been found in moderate, uncomplicated hypertension. Moreover, acute lowering of blood pressure facilitated the release of vasopressin and its osmoregulation while a chronic antihypertensive treatment did not interfere with a normal control of vasopressin secretion.
D000959:Antihypertensive Agents / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D003000:Clonidine / Q000494:pharmacology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D007030:Hypothalamo-Hypophyseal System / Q000502:physiology; D007038:Hypotonic Solutions / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009599:Nitroprusside / Q000494:pharmacology; D011187:Posture / Q000502:physiology; D012462:Saline Solution, Hypertonic / Q000494:pharmacology; D014667:Vasopressins / Q000097:blood* / Q000378:metabolism; D014882:Water-Electrolyte Balance / Q000187:drug effects / Q000502:physiology*
D000959:Antihypertensive Agents; D007038:Hypotonic Solutions; D012462:Saline Solution, Hypertonic; D014667:Vasopressins; D009599:Nitroprusside; D003000:Clonidine